ArticleSkin health and disease2025
Intranasal corticosteroids: a promising new approach for adults with chronic idiopathic urticaria linked to aeroallergens - a double-blind randomized clinical trial.
Article in Skin health and disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Aeroallergens in Atopic Dermatitis and Chronic Urticaria.Current allergy and asthma reports · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Chronic idiopathic urticaria (CIU) is a debilitating condition characterized by recurrent hives, itching and angioedema lasting for more than 6 weeks without an identifiable cause. It significantly impacts quality of life, causing physical discomfort and emotional distress. CIU's complex pathophysiology involves immune interactions, mast cells and histamine release, with aeroallergens potentially exacerbating symptoms in sensitized patients. Current treatments primarily involve antihistamines, but many patients experience inadequate relief, prompting the exploration of alternative therapies. Intranasal corticosteroids, typically used for allergic rhinitis, may offer potential benefits for CIU, although evidence of their efficacy is limited. Objectives: To investigate the effect of intranasal corticosteroids in adults with CIU who had a positive skin prick test for aeroallergens. Methods: In this double-blind placebo-controlled trial, 69 adults with CIU sensitized to aeroallergens received budesonide 32 µg per actuation, 2 sprays per nostril twice daily or identical placebo for 6 months while maintained on a stable single-agent nonsedating H1 antihistamine. Participants were randomly assigned to receive either budesonide or placebo. Outcomes included changes in urticaria symptoms and Urticaria Severity Score and quality of life. The study was registered with the Iranian Registry of Clinical Trials (IRCT 20231229060563N1). Results: At baseline, both groups were comparable. Post-treatment, participants in the corticosteroid group showed a greater reduction in Urticaria Activity Score (mean difference = 4.25, Conclusions: Intranasal corticosteroids were effective in reducing urticaria symptoms but did not offer significant benefits over placebo with regard to overall quality of life. The results highlight the complexity of CIU management and suggest a potential placebo effect.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.